ARD-69 represents a potent proteolysis-targeting chimera (PROTAC) designed specifically for the degradation of the androgen receptor (AR). It serves as a proof-of-concept lead to assess the viability of PROTAC technology as an innovative treatment approach for castration-resistant prostate cancer with AR positivity.
Usually ships within 24 hours.